Ehlers and Lin move up ladder at Pfizer; Gutierrez-Ramos out
Pfizer Inc. announced two key appointments Wednesday: Michael D. Ehlers as head of research and development for its BioTherapeutics unit and John Lin as chief scientific officer of its Rinat division.
Ehlers, who also has been named a senior vice president and site head for Pfizer's research sites in Boston and Cambridge, Mass., replaces José-Carlos Gutiérrez-Ramos, who Pfizer reported "has decided to return to the biotech sector in the Cambridge area."
Ehlers will report directly to Mikael Dolsten, president of Pfizer's worldwide R&D. Lin, who succeeds Jaume Pons, reports to Robert T. Abraham, senior vice president for Oncology-Rinat Research & Development in San Francisco.
Ehlers, to be based in Cambridge, will maintain his title as chief scientific officer of Pfizer’s Neuroscience and Pain Research Unit.
l.howard@theday.com
Twitter: @KingstonLeeHow
Comment threads are monitored for 48 hours after publication and then closed.
